Introducing a new High-throughput Fully Humanized Antibody Discovery Platform with Biointron AbDrop™ & Cyagen HUGO-Ab™! This integrated approach combines microfluidics technology and humanized mice models for single B cell antibody discovery and fully human antibody generation, offering a safer, faster and more efficient solution for fully human antibody discovery process, delivering validated candidates in as quickly as 3 months.
The process begins with animal immunization using HUGO-Ab® mice, which are genetically engineered to produce fully human antibodies using TurboKnockout® ES technology. This technology replaces the endogenous VH and VL genes by fully human VH and VL genes in situ to offer more stable phenotypic and functional outcomes in progeny compared to traditional transgenic methods. Humanizing the whole heavy and light chain V(D)J variable regions offers greater genetic diversity and low immunogenicity for antibody development, in addition to a more diverse antibody repertoire generation from V(D)J recombination to ensure an immune response like that of wild mice when exposed to antigens.
TurboKnockout® gene-editing technology based on embryonic stem (ES) targeting retains the advantages of traditional ES targeting such as maturity, precise modification, and stable results. It works by microinjection at specific embryonic development stages, so TurboKnockout® ES cells can completely replace endogenous ES cells. Therefore, we bypass the "chimeric" stage and shorten the ES targeting production cycle to as short as 4 months, reducing the breeding time by two generations. This makes it the preferred method for constructing complex models, such as those requiring large segment gene modifications.
HUGO-Ab™ mice provide a robust platform for generating antibodies that mimic the human immune response. This ensures higher immune response variability, improving the quality and diversity of resulting antibody molecules which is essential for therapeutic applications.
This technology supports a faster transition from immunization to the single B cell screening process, enabling rapid access to therapeutic candidates.
Biointron's AbDrop™ platform leverages microfluidic technology as the screening method to generate droplets encapsulating individual plasma cells. Once the B cells are collected from the mice, each single B cell will be encapsulated with a labeled antigen and a labeled secondary antibody in a macro-droplet. FRET fluorescence is induced so the chip can sort positive droplets, which will then be emulsified to release the cells for sequencing. Screening and enrichment of 1-2 million plasma B cells can be completed within a single day, and hundreds of naturally paired heavy & light chains are obtained at a single time. Afterward, NGS sequencing, high-throughput expression and validation, and data analysis will be conducted in one week, and overall, it will take one month from screening to purified antibody candidates with validated activity.
Researchers use microfluidic technology for antibody development to manipulate small fluid volumes within microfabricated channels, offering precise control over experimental conditions and enabling high-throughput testing. This technology reduces reagent consumption, enhances reaction kinetics, and integrates multiple development steps into a single device, improving efficiency, speed, and precision in antibody production and screening. Compared to other single B cell technologies, AbDrop™ has several advantages:
From immunization to functional validation, the platform accelerates the antibody drug discovery cycle to as little as 12 weeks.
Native B cell pairing and fully human V(D)J regions support a wide range of therapeutic options with minimized off-target effects.
Our High-throughput Fully Human Antibody Discovery Platform eliminates the need for complex modifications and simplifies the development process, reducing costs and accelerating the discovery of safer and more effective antibody drugs.
Fully human antibodies
Faster screening timelines
High-throughput sequencing
TurboKnockout® for rapid progress
Our High-throughput Fully Human Antibody Discovery Platform eliminates the need for complex modifications and simplifies the development process, reducing costs and accelerating the discovery of safer and more effective antibody drugs.
To learn more, visit the service page here, or contact our expert team at info@biointron.com, or by phone at +1(732)790-8340.
PEGS Europe2025 conference was held inLisbon, Portugal, fromNovember11to Novembe……
Antibody discovery has traditionally relied on selecting clones based on target ……
The Society for Immunotherapy of Cancer (SITC) 2025 conference was held in Natio……
A VHH library is a collection of variable domains of heavy-chain antibodies (VHH……
You can also contact us on the Scientist and Science Exchange marketplaces.
